InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,884.00
(
-2.28%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
70.90
(
0.00%
)
Bitcoin
91,590.56
(
0.58%
)
Post# of 253623
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120734
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 116910

Wednesday, 04/20/2011 8:35:16 PM

Wednesday, April 20, 2011 8:35:16 PM

Post# of 253623
GS7340 is GILD’s lifecycle management answer to the expiration of patent protection on Viread/Truvada in 2017. GS7340, a prodrug of tenofovir, is more potent at 50mg than Viread (also a prodrug of tenofovir) is at 300mg, according to GILD’s 1Q11 CC.

As a result, GILD will test GS7340 doses as low as 8mg (!) in the next phase-1b trial. A combination pill consisting of GS7340 + Emtriva has already been formulated and will begin PK testing in 2Q11.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up